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years at a rate of 6.9 visits/1000 persons annually (95%CI: 5.1,
8.7) compared to children 5–17 years at 8.5 visits/1000 persons
annually (95%CI: 5.6, 11.3). Visits to ofﬁce-based physicians,
hospital emergency departments and outpatient departments
accounted for 85%, 11% and 5% of visits, respectively. 
Antibiotics were prescribed at 2.5 million visits (38% of encoun-
ters) at an estimated cost of $93 million. Broad-spectrum 
antibiotics prescribed at 39% of visits where an antibiotic was
prescribed accounted for $59 million of the total cost for antibi-
otics. Combined visit and antibiotic costs for the group totaled
$441 million. CONCLUSIONS: Prescribing of antibiotics for
inﬂuenza is widespread, increases medical costs and may con-
tribute to antibiotic resistance. Increased use of vaccination 
and viral testing could reduce antibiotic use and result in cost
savings.
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OBJECTIVES: To evaluate the costs and outcomes of extended-
release clarithromycin versus clarithromycin immediate-release
for outpatients with bacterial lower respiratory tract infections
(LRTIs, community-acquired pneumonia and acute exacerba-
tions of chronic bronchitis). METHODS: We developed a 
decision-analysis model comparing extended-release clar-
ithromycin with immediate-release for LRTIs. Treatment success
and adverse event (AE) rates were derived from weighted aver-
ages of identiﬁed published studies that included dichotomous
variables for cure vs. failure (16 immediate-release studies, 4
extended-release). Costs were standard US values. The model
included the acute antibiotic treatment period (start of ﬁrst-line
therapy through completion of second-line therapy, if applica-
ble). The model measured the proportion of patients cured on
ﬁrst- and second-line therapy, patients discontinuing due to AEs
and lack of efﬁcacy, and physician, antibiotic, and total costs per
episode. RESULTS: More patients achieved clinical cure with
clarithromycin extended-release (83.9%) than with clar-
ithromycin immediate-release (72.8%); AE discontinuation rates
were lower for the extended-release group (2.4% versus 4.9%
for the immediate-release group). Total costs with clarithromycin
extended-release were $32 (16%) less than total costs for imme-
diate-release. Sensitivity analyses indicated that the model is
robust to changes in cure and AE discontinuation rates within
reasonable ranges. Incorporating greater treatment adherence for
extended-release (once-daily) versus immediate-release (twice-
daily) therapy resulted in greater cost savings for clarithromycin
extended-release. CONCLUSIONS: Clarithromycin extended-
release is cost saving compared with clarithromycin immediate-
release for LRTIs, using base-case results. The model did not
include hospitalization, which is uncommon in mild to moder-
ate LRTIs; addition of hospitalizations is likely to demonstrate
additional costs savings with clarithromycin extended-release.
These differences in clinical and economic results are important
in that extended-release therapy can lead to improved patient
outcomes with decreased costs. Further research is needed to
determine the cause and impacts of these differences in efﬁcacy
and tolerability.
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OBJECTIVE: To do a cost-effectiveness analysis of the intro-
duction of meningococcal vaccine type C (NeisVac-CTM) in Por-
tugal. METHODS: Model: The study compared vaccine with no
vaccination for a cohort of 100.000 for lifetime using a Markov
model. Scenarios for age of vaccine administration: children with
less than one year of age, children with one year of age and chil-
dren with two years of age. The outcomes measured were avoid-
able cases, avoidable death, avoidable disability and avoidable
years of life lost. RESULTS: For the case base studied the cost
per year of life gained (or lost year of prevented life) for the
NeisVac-CTM was 6372€ for vaccination administer after the ﬁrst
year of life and of 12,635€ for vaccination administer during the
ﬁrst year of life. Difference is explained by the need of two doses
of vaccine during the ﬁrst year of life and only one for the other
scenario. These costs includes the cost of vaccines, the effect and
consequences of vaccines in the consumption of resources of the
health system (hospital, outpatients, medicines, exams, etc.),
direct costs for the State other than of the health system (support
of the Social Welfare and the deﬁcient ones) and the indirect costs
generated by the effect of the disease in the productivity lost by
the families in the case of children or of the self in the case of
disease while in active labor age. Sensitivity analysis showed the
robustness of these values. CONCLUSIONS: Compared with
other interventions routinely done by the National Health
Service the administration of the of the NeisVac-CTM it can be
considered cost-effective for the Portuguese population.
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OBJECTIVE: This study examines the beneﬁt of physician pro-
ﬁling on cost and utilization of antibiotics. METHODS: General
Practitioners, Family Practitioners, Internists and Pediatricians
were sent an education tool regarding the appropriate use of
antibiotics for the treatment of respiratory illnesses for the
2000–01, 2001–02 and 2002–03 seasons. Physicians who pre-
scribed greater than 60 antibiotics in the previous year also
received a proﬁle of their ﬁrst line antibiotic use. The average
ingredient cost per prescription for proﬁled vs. non-proﬁled
physicians was used to determine the impact of physician pro-
ﬁling on antibiotic prescribing behavior. Physicians were also
surveyed during the 2000/01 season on the usefulness of the edu-
cation tool and the proﬁle. RESULTS: Approximately seventeen
thousand physicians were targeted for each season. The ingredi-
ent cost per prescription for ﬁrst line antibiotics was signiﬁcantly
lower for proﬁled (N = 3286) vs. non proﬁled physicians in all
three seasons: $5.19 vs. $5.31 (p < 0.0001) for season 1; $6.29
vs. $6.57 (p < 0.0001) for season 2; and $8.39 vs. $8.57 (p =
0.0003) for season 3. The ingredient cost per prescription was
also lower for second line antibiotics in the proﬁled vs. non-pro-
ﬁled groups for each consecutive season: $55.35 vs. $67.09 (p =
0.057), $56.53 vs. $57.35 (p < 0.0001), and $56.58 vs. $57.22
(p = 0.0001), respectively. Out of the 4.1% of physicians who
responded to the program survey, 84% agreed that the infor-
mation in the education tool was informative and useful. Seventy
